Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Completed · Phase 1

Conditions studied: Acute Myeloid Leukemia

In brief

A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

Key facts

Study ID

NCT00926731

Run by

AstraZeneca

People needed

4

Starts

2009-06-01

Expected to finish

2011-05-01

Last updated by the study team

2011-06-16

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed patient.
• Provision of written informed consent.
• De Novo (primary) or Secondary AML.
• Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons.

You may not qualify if…

• Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL).
• Patients with blast crisis of chronic myeloid leukaemia.
• Persistent, chronic, clinically significant toxicities from any prior anti- cancer therapy greater than CTCAE Grade 1 (except alopecia).

Where it is running

• Research Site — Cleveland, Ohio, United States
• Research Site — Houston, Texas, United States
• Research Site — Le Chesnay, France
• Research Site — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.